{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T02:22:37Z","timestamp":1783131757041,"version":"3.54.6"},"reference-count":214,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100021856","name":"Ministero dell&apos;Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["CUP H53D23007500001"],"award-info":[{"award-number":["CUP H53D23007500001"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.autrev.2026.104073","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T23:34:53Z","timestamp":1778196893000},"page":"104073","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inflammatory biomarkers of atherosclerosis in SLE that may improve SLE-specific cardiovascular risk assessment tools"],"prefix":"10.1016","volume":"25","author":[{"given":"Silvia","family":"De Santis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Prete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Liakouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Vomero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Navarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Ruscitti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ciccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Giacomelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Favoino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Perosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.autrev.2026.104073_bb0005","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1191\/0961203306lu2305xx","article-title":"Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden","volume":"15","author":"Danchenko","year":"2006","journal-title":"Lupus"},{"issue":"3","key":"10.1016\/j.autrev.2026.104073_bb0010","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard-2022-223035","article-title":"Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study","volume":"82","author":"Tian","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"14","key":"10.1016\/j.autrev.2026.104073_bb0015","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1177\/0961203316644333","article-title":"Differences in disease phenotype and severity in SLE across age groups","volume":"25","author":"Ambrose","year":"2016","journal-title":"Lupus"},{"issue":"9","key":"10.1016\/j.autrev.2026.104073_bb0020","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41584-025-01277-y","article-title":"Addressing the challenge of global delays in diagnosis and treatment of systemic lupus erythematosus","volume":"21","author":"Pons-Estel","year":"2025","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104073_bb0025","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/acr.22173","article-title":"Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies","volume":"66","author":"Yurkovich","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"10.1016\/j.autrev.2026.104073_bb0030","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/rheumatology\/kex412","article-title":"Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999-2014)","volume":"57","author":"Jorge","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.autrev.2026.104073_bb0035","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/art.21955","article-title":"Mortality in systemic lupus erythematosus","volume":"54","author":"Bernatsky","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.autrev.2026.104073_bb0040","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1136\/annrheumdis-2017-211663","article-title":"Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016","volume":"76","author":"Tektonidou","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2026.104073_bb0045","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1136\/annrheumdis-2018-214802","article-title":"All-cause, cause-specific and age-specific standardised mortality ratios of patients with systemic lupus erythematosus in Ontario, Canada over 43 years (1971-2013)","volume":"78","author":"Tselios","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.autrev.2026.104073_bb0050","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/rheumatology\/kei142","article-title":"\u2018Not only\u2026but also\u2019: factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus","volume":"44","author":"Bruce","year":"2005","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.autrev.2026.104073_bb0055","first-page":"267","article-title":"Severe pulmonary hypertension as the initial manifestation of systemic lupus erythematosus: a case report and review of the literature","volume":"32","author":"Prete","year":"2014","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104073_bb0060","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.revmed.2014.10.009","article-title":"Screening and management of cardiovascular risk factors in systemic lupus erythematosus: Recommendations for clinical practice based on the literature and expert opinion","volume":"36","author":"Arnaud","year":"2015","journal-title":"Rev Med Interne"},{"issue":"10354","key":"10.1016\/j.autrev.2026.104073_bb0065","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(22)01349-6","article-title":"Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK","volume":"400","author":"Conrad","year":"2022","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.autrev.2026.104073_bb0070","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1177\/09612033221147471","article-title":"Cardiovascular events and risk in patients with systemic lupus erythematosus: Systematic literature review and meta-analysis","volume":"32","author":"Bello","year":"2023","journal-title":"Lupus"},{"issue":"9","key":"10.1016\/j.autrev.2026.104073_bb0075","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.15339","article-title":"T-cell senescence was correlated with early atherosclerosis in patients with systemic lupus erythematosus","volume":"27","author":"Pratama","year":"2024","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2026.104073_bb0080","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keaf458","article-title":"Arterial stiffness in different age and cardiovascular risk groups of patients with systemic lupus erythematosus","volume":"65","author":"Soufla","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2026.104073_bb0085","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/rheumatology\/keab362","article-title":"All-cause and cause-specific mortality in systemic lupus erythematosus: a population-based study","volume":"61","author":"Moghaddam","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.autrev.2026.104073_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2025.103760","article-title":"Immunomodulation for accelerated atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus","volume":"24","author":"Bartoloni","year":"2025","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1016\/j.autrev.2026.104073_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26073071","article-title":"Chronic inflammatory diseases and cardiovascular risk: current insights and future strategies for optimal management","volume":"26","author":"Cacciatore","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2026.104073_bb0100","doi-asserted-by":"crossref","first-page":"1543157","DOI":"10.3389\/fimmu.2025.1543157","article-title":"Ocular markers of microangiopathy and their possible association with cardiovascular risk in patients with systemic inflammatory rheumatic diseases: a systematic review","volume":"16","author":"Sturm","year":"2025","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.autrev.2026.104073_bb0105","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1002\/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I","article-title":"Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus","volume":"44","author":"Esdaile","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.autrev.2026.104073_bb0110","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1177\/0961203307081113","article-title":"Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort","volume":"16","author":"Urowitz","year":"2007","journal-title":"Lupus"},{"issue":"5","key":"10.1016\/j.autrev.2026.104073_bb0145","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3899\/jrheum.150983","article-title":"Modified framingham risk factor score for systemic lupus erythematosus","volume":"43","author":"Urowitz","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2026.104073_bb0150","article-title":"Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study","volume":"357","author":"Hippisley-Cox","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2026.104073_bb1075","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X221092373","article-title":"SCORE2 versus SCORE in patients with systemic lupus erythematosus","volume":"14","author":"Quevedo-Abeledo","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"1","key":"10.1016\/j.autrev.2026.104073_bb0155","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/art.38204","article-title":"A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus","volume":"66","author":"McMahon","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104073_bb0975","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/acr2.11223","article-title":"A panel of biomarkers associates with increased risk for cardiovascular events in women with systemic lupus erythematosus","volume":"3","author":"Skaggs","year":"2021","journal-title":"ACR Open Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104073_bb0135","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2019-000346","article-title":"Development of a systemic lupus erythematosus cardiovascular risk equation","volume":"6","author":"Petri","year":"2019","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.autrev.2026.104073_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152468","article-title":"Personalizing cardiovascular risk prediction for patients with systemic lupus erythematosus","volume":"67","author":"Choi","year":"2024","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2026.104073_bb0115","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2026.104073_bb0120","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1136\/annrheumdis-2021-221733","article-title":"EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome","volume":"81","author":"Drosos","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2026.104073_bb0125","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.autrev.2026.104073_bb0130","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S2665-9913(24)00090-0","article-title":"Prevalence and target attainment of traditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countries","volume":"6","author":"Bolla","year":"2024","journal-title":"Lancet Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104073_bb0140","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/eurjpc\/zwaa256","article-title":"Underperformance of clinical risk scores in identifying vascular ultrasound-based high cardiovascular risk in systemic lupus erythematosus","volume":"28","author":"Drosos","year":"2021","journal-title":"Eur J Prev Cardiol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104073_bb0165","first-page":"509","article-title":"Evaluating the metabolic score for insulin resistance in patients with systemic lupus erythematosus","volume":"44","author":"Aznar-Esquivel","year":"2025","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104073_bb0170","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.autrev.2017.11.028","article-title":"Oxidized low density lipoproteins: The bridge between atherosclerosis and autoimmunity. Possible implications in accelerated atherosclerosis and for immune intervention in autoimmune rheumatic disorders","volume":"17","author":"Suciu","year":"2018","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.autrev.2026.104073_bb0175","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2174\/1570161118666191227101636","article-title":"Cardiovascular disease in systemic lupus erythematosus: recent data on epidemiology, risk factors and prevention","volume":"18","author":"Kostopoulou","year":"2020","journal-title":"Curr Vasc Pharmacol"},{"issue":"50","key":"10.1016\/j.autrev.2026.104073_bb0180","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000040773","article-title":"Exploring novel markers for coronary heart disease associated with systemic lupus erythematosus: a review","volume":"103","author":"Du","year":"2024","journal-title":"Medicine (Baltimore)"},{"issue":"14","key":"10.1016\/j.autrev.2026.104073_bb0185","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14145133","article-title":"Serum concentrations of vascular endothelial growth factor in polish patients with systemic lupus erythematosus are associated with cardiovascular risk and autoantibody profiles","volume":"14","author":"Fischer","year":"2025","journal-title":"J Clin Med"},{"issue":"7","key":"10.1016\/j.autrev.2026.104073_bb0190","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/eurheartj\/ehr304","article-title":"Nitric oxide synthases: regulation and function","volume":"33","author":"Forstermann","year":"2012","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.autrev.2026.104073_bb0195","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/BF03401781","article-title":"Inducible nitric oxide synthase and inflammatory diseases","volume":"6","author":"Zamora","year":"2000","journal-title":"Mol Med"},{"issue":"11","key":"10.1016\/j.autrev.2026.104073_bb0200","doi-asserted-by":"crossref","first-page":"9142","DOI":"10.1074\/jbc.M211394200","article-title":"High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases","volume":"278","author":"Mineo","year":"2003","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.autrev.2026.104073_bb0205","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26031204","article-title":"Advances in the regulation of inflammatory mediators in nitric oxide synthase: implications for disease modulation and therapeutic approaches","volume":"26","author":"Kim","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.autrev.2026.104073_bb0210","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1161\/01.RES.0000217594.97174.c2","article-title":"Coupled and uncoupled NOS: separate but equal? Uncoupled NOS in endothelial cells is a critical pathway for intracellular signaling","volume":"98","author":"Sullivan","year":"2006","journal-title":"Circ Res"},{"issue":"5","key":"10.1016\/j.autrev.2026.104073_bb0215","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1537-1891(02)00250-1","article-title":"Vasoactive substances: nitric oxide and endothelial dysfunction in atherosclerosis","volume":"38","author":"Russo","year":"2002","journal-title":"Vascul Pharmacol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104073_bb0220","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1023\/A:1022199021949","article-title":"Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction","volume":"8","author":"Anderson","year":"2003","journal-title":"Heart Fail Rev"},{"issue":"2","key":"10.1016\/j.autrev.2026.104073_bb0225","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1161\/01.RES.76.2.199","article-title":"cGMP and nitric oxide modulate thrombin-induced endothelial permeability. Regulation via different pathways in human aortic and umbilical vein endothelial cells","volume":"76","author":"Draijer","year":"1995","journal-title":"Circ Res"},{"issue":"7","key":"10.1016\/j.autrev.2026.104073_bb0230","article-title":"Nitric oxide increases arterial endotheial permeability through mediating VE-cadherin expression during arteriogenesis","volume":"10","author":"Yang","year":"2015","journal-title":"PloS One"},{"issue":"11","key":"10.1016\/j.autrev.2026.104073_bb0235","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1073\/pnas.88.11.4651","article-title":"Nitric oxide: an endogenous modulator of leukocyte adhesion","volume":"88","author":"Kubes","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.autrev.2026.104073_bb0240","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1097-4652(199707)172:1<12::AID-JCP2>3.0.CO;2-G","article-title":"Nitric oxide inhibits neutrophil beta 2 integrin function by inhibiting membrane-associated cyclic GMP synthesis","volume":"172","author":"Banick","year":"1997","journal-title":"J Cell Physiol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104073_bb0245","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1172\/JCI119540","article-title":"Nitric oxide released from activated platelets inhibits platelet recruitment","volume":"100","author":"Freedman","year":"1997","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.autrev.2026.104073_bb0250","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0922-4106(90)90031-R","article-title":"Inhibition by nitric oxide and nitric oxide-producing vasodilators of DNA synthesis in vascular smooth muscle cells","volume":"189","author":"Nakaki","year":"1990","journal-title":"Eur J Pharmacol"},{"issue":"10","key":"10.1016\/j.autrev.2026.104073_bb0255","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1046\/j.1538-7836.2003.00345.x","article-title":"Nitric oxide in vascular biology","volume":"1","author":"Walford","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.autrev.2026.104073_bb0260","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1172\/JCI118074","article-title":"Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines","volume":"96","author":"De","year":"1995","journal-title":"J Clin Invest"},{"issue":"16","key":"10.1016\/j.autrev.2026.104073_bb0265","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"352","author":"Hansson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104073_bb0270","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.cca.2013.06.006","article-title":"Foam cells in atherosclerosis","volume":"424","author":"Yu","year":"2013","journal-title":"Clin Chim Acta"},{"issue":"5","key":"10.1016\/j.autrev.2026.104073_bb0275","doi-asserted-by":"crossref","first-page":"H1679","DOI":"10.1152\/ajpheart.2000.278.5.H1679","article-title":"Role of endogenous nitric oxide in progression of atherosclerosis in apolipoprotein E-deficient mice","volume":"278","author":"Kauser","year":"2000","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"7","key":"10.1016\/j.autrev.2026.104073_bb0280","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1111\/j.1476-5381.2009.00630.x","article-title":"Atherosclerosis induced by chronic inhibition of the synthesis of nitric oxide in moderately hypercholesterolaemic rabbits is suppressed by pitavastatin","volume":"159","author":"Kitahara","year":"2010","journal-title":"Br J Pharmacol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104073_bb0285","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1172\/JCI8376","article-title":"Enhanced atherosclerosis and kidney dysfunction in eNOS(-\/-)Apoe(-\/-) mice are ameliorated by enalapril treatment","volume":"105","author":"Knowles","year":"2000","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.autrev.2026.104073_bb0290","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.carpath.2008.08.005","article-title":"Inducible and endothelial nitric oxide synthase expression in human atherogenesis: an immunohistochemical and ultrastructural study","volume":"18","author":"Perrotta","year":"2009","journal-title":"Cardiovasc Pathol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104073_bb0295","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1172\/JCI119131","article-title":"Tetrahydrobiopterin restores endothelial function in hypercholesterolemia","volume":"99","author":"Stroes","year":"1997","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.autrev.2026.104073_bb0300","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1074\/jbc.272.2.1276","article-title":"Subunit interactions of endothelial nitric-oxide synthase. Comparisons to the neuronal and inducible nitric-oxide synthase isoforms","volume":"272","author":"Venema","year":"1997","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.autrev.2026.104073_bb0305","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1172\/JCI4829","article-title":"Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase","volume":"103","author":"Feron","year":"1999","journal-title":"J Clin Invest"},{"issue":"25","key":"10.1016\/j.autrev.2026.104073_bb0310","doi-asserted-by":"crossref","first-page":"22546","DOI":"10.1074\/jbc.M302227200","article-title":"Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase","volume":"278","author":"Kuzkaya","year":"2003","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.autrev.2026.104073_bb0315","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0008-6363(02)00617-X","article-title":"ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins","volume":"57","author":"Sydow","year":"2003","journal-title":"Cardiovasc Res"},{"issue":"12","key":"10.1016\/j.autrev.2026.104073_bb0320","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.freeradbiomed.2004.03.019","article-title":"Homocysteine induces oxidative stress by uncoupling of NO synthase activity through reduction of tetrahydrobiopterin","volume":"36","author":"Topal","year":"2004","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104073_bb0325","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1152\/physrev.00029.2006","article-title":"Nitric oxide and peroxynitrite in health and disease","volume":"87","author":"Pacher","year":"2007","journal-title":"Physiol Rev"},{"key":"10.1016\/j.autrev.2026.104073_bb0330","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1755-1536-7-13","article-title":"Impaired Cav-1 expression in SSc mesenchymal cells upregulates VEGF signaling: a link between vascular involvement and fibrosis","volume":"7","author":"Cipriani","year":"2014","journal-title":"Fibrogenesis Tissue Repair"},{"issue":"2","key":"10.1016\/j.autrev.2026.104073_bb0335","doi-asserted-by":"crossref","first-page":"E335","DOI":"10.1152\/ajpendo.00320.2015","article-title":"Insulin decreases atherosclerotic plaque burden and increases plaque stability via nitric oxide synthase in apolipoprotein E-null mice","volume":"311","author":"Mori","year":"2016","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"10\u201311","key":"10.1016\/j.autrev.2026.104073_bb0340","first-page":"1343","article-title":"Regulation of the expression of inducible nitric oxide synthase","volume":"384","author":"Kleinert","year":"2003","journal-title":"Biol Chem"},{"issue":"3","key":"10.1016\/j.autrev.2026.104073_bb0345","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.clim.2006.06.001","article-title":"The biology of nitric oxide and other reactive intermediates in systemic lupus erythematosus","volume":"121","author":"Oates","year":"2006","journal-title":"Clin Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104073_bb0350","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/ar3045","article-title":"Central role of nitric oxide in the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus","volume":"12","author":"Nagy","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2026.104073_bb0355","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12865-020-0335-7","article-title":"Inducible nitric oxide synthase and systemic lupus erythematosus: a systematic review and meta-analysis","volume":"21","author":"Pan","year":"2020","journal-title":"BMC Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104073_bb0360","doi-asserted-by":"crossref","DOI":"10.3390\/jpm13060934","article-title":"The Inflammatory profile orchestrated by inducible nitric oxide synthase in systemic lupus erythematosus","volume":"13","author":"Ene","year":"2023","journal-title":"J Pers Med"},{"key":"10.1016\/j.autrev.2026.104073_bb0365","doi-asserted-by":"crossref","first-page":"1417981","DOI":"10.1155\/2020\/1417981","article-title":"Role of the eNOS uncoupling and the nitric oxide metabolic pathway in the pathogenesis of autoimmune rheumatic diseases","volume":"2020","author":"Luczak","year":"2020","journal-title":"Oxid Med Cell Longev"},{"issue":"1","key":"10.1016\/j.autrev.2026.104073_bb0370","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2025-001568","article-title":"Lupus nephritis serum induces changes in gene expression in human glomerular endothelial cells, which is modulated by L-sepiapterin: implications for redox-mediated endothelial dysfunction","volume":"12","author":"Russell","year":"2025","journal-title":"Lupus Sci Med"},{"issue":"3","key":"10.1016\/j.autrev.2026.104073_bb0375","first-page":"508","article-title":"The association of endothelial nitric oxide synthase gene single nucleotide polymorphisms with paediatric systemic lupus erythematosus","volume":"36","author":"Zhu","year":"2018","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"10.1016\/j.autrev.2026.104073_bb0380","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1007\/s00393-016-0157-4","article-title":"Associations between eNOS polymorphisms and susceptibility to systemic lupus erythematosus and rheumatoid arthritis: \u00e2 meta-analysis","volume":"76","author":"Lee","year":"2017","journal-title":"Z Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104073_bb0385","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00011-009-7215-1","article-title":"Widespread expression of inducible NOS and citrulline in lupus nephritis tissues","volume":"58","author":"Goytia","year":"2009","journal-title":"Inflamm Res"},{"issue":"4","key":"10.1016\/j.autrev.2026.104073_bb0390","first-page":"404","article-title":"Expression of inducible nitric oxide synthase and apoptosis in human lupus nephritis","volume":"77","author":"Wang","year":"1997","journal-title":"Nephron"},{"issue":"6","key":"10.1016\/j.autrev.2026.104073_bb0395","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.3727\/096368917X694660","article-title":"Human umbilical cord mesenchymal stem cells inhibit T follicular helper cell expansion through the activation of iNOS in Lupus-Prone B6.MRL-Fas(lpr) mice","volume":"26","author":"Zhang","year":"2017","journal-title":"Cell Transplant"},{"issue":"7","key":"10.1016\/j.autrev.2026.104073_bb0400","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2310\/6650.2005.53705","article-title":"Inducible nitric oxide synthase inhibitors reduce urinary markers of systemic oxidant stress in murine proliferative lupus nephritis","volume":"53","author":"Njoku","year":"2005","journal-title":"J Invest Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104073_bb0405","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/art.23153","article-title":"Association of serum nitrate and nitrite levels with longitudinal assessments of disease activity and damage in systemic lupus erythematosus and lupus nephritis","volume":"58","author":"Oates","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.autrev.2026.104073_bb0410","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1002\/art.1780401013","article-title":"Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus","volume":"40","author":"Belmont","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2026.104073_bb0415","first-page":"318","article-title":"Correlation of serum measures of nitric oxide production with lupus disease activity","volume":"26","author":"Gilkeson","year":"1999","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2026.104073_bb0420","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1177\/0961203311411350","article-title":"Oxidative stress is associated with liver damage, inflammatory status, and corticosteroid therapy in patients with systemic lupus erythematosus","volume":"20","author":"Lozovoy","year":"2011","journal-title":"Lupus"},{"issue":"10","key":"10.1016\/j.autrev.2026.104073_bb0425","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1177\/0961203317692436","article-title":"Reduction of nitric oxide and DNA\/RNA oxidation products are associated with active disease in systemic lupus erythematosus patients","volume":"26","author":"Iriyoda","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2026.104073_bb0430","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.coi.2020.10.014","article-title":"Type I interferon in the pathogenesis of systemic lupus erythematosus","volume":"67","author":"Postal","year":"2020","journal-title":"Curr Opin Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104073_bb0435","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.coi.2004.09.014","article-title":"The emerging role of interferon in human systemic lupus erythematosus","volume":"16","author":"Baechler","year":"2004","journal-title":"Curr Opin Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104073_bb0440","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/art.21031","article-title":"Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease","volume":"52","author":"Kirou","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.autrev.2026.104073_bb0445","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1002\/art.22044","article-title":"Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus","volume":"54","author":"Feng","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.autrev.2026.104073_bb0450","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1002\/art.21890","article-title":"Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies","volume":"54","author":"Hua","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.autrev.2026.104073_bb0455","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00109-016-1421-4","article-title":"Cause and consequences of the activated type I interferon system in SLE","volume":"94","author":"Eloranta","year":"2016","journal-title":"J Mol Med (Berl)"},{"issue":"1","key":"10.1016\/j.autrev.2026.104073_bb0460","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2016-000202","article-title":"Single-cell gene expression patterns in lupus monocytes independently indicate disease activity, interferon and therapy","volume":"4","author":"Jin","year":"2017","journal-title":"Lupus Sci Med"},{"issue":"6","key":"10.1016\/j.autrev.2026.104073_bb0465","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/annrheumdis-2021-221835","article-title":"Serum interferon-\u00ce\u00b1 levels and IFN type I-stimulated genes score perform equally to assess systemic lupus erythematosus disease activity","volume":"81","author":"Chasset","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2026.104073_bb0470","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/art.30165","article-title":"Interferon-alpha priming promotes lipid uptake and macrophage-derived foam cell formation: a novel link between interferon-alpha and atherosclerosis in lupus","volume":"63","author":"Li","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.autrev.2026.104073_bb0475","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.4049\/jimmunol.1600108","article-title":"IFN-alpha negatively regulates the expression of endothelial nitric oxide synthase and nitric oxide production: implications for systemic lupus erythematosus","volume":"199","author":"Buie","year":"2017","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.autrev.2026.104073_bb0480","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.4049\/jimmunol.169.8.4279","article-title":"Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection","volume":"169","author":"Nguyen","year":"2002","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104073_bb0485","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4049\/jimmunol.182.1.34","article-title":"Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo","volume":"182","author":"Kariuki","year":"2009","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.autrev.2026.104073_bb0490","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084450","article-title":"Association of STAT4 polymorphism with severe renal insufficiency in lupus nephritis","volume":"8","author":"Bolin","year":"2013","journal-title":"PloS One"},{"issue":"5","key":"10.1016\/j.autrev.2026.104073_bb0495","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1136\/ard.2009.115535","article-title":"A STAT4 risk allele is associated with ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus erythematosus","volume":"69","author":"Svenungsson","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2026.104073_bb0500","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1182\/blood-2007-05-089086","article-title":"Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis","volume":"110","author":"Denny","year":"2007","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.autrev.2026.104073_bb0505","doi-asserted-by":"crossref","first-page":"6143","DOI":"10.4049\/jimmunol.1101284","article-title":"Inflammasome activation of IL-18 results in endothelial progenitor cell dysfunction in systemic lupus erythematosus","volume":"187","author":"Kahlenberg","year":"2011","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.autrev.2026.104073_bb0510","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s10067-010-1386-6","article-title":"Expressions of IL-18 and its binding protein in peripheral blood leukocytes and kidney tissues of lupus nephritis patients","volume":"29","author":"Hu","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2026.104073_bb0515","doi-asserted-by":"crossref","unstructured":"Thacker SG, Berthier CC, Mattinzoli D, Rastaldi MP, Kretzler M, Kaplan MJ. The detrimental effects of IFN-alpha on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction. J Immunol 2010 Octob185(7):4457-69.","DOI":"10.4049\/jimmunol.1001782"},{"key":"10.1016\/j.autrev.2026.104073_bb0520","doi-asserted-by":"crossref","unstructured":"Svenungsson E, Jensen-Urstad K, Heimburger M, Silveira A, Hamsten A, de FU et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001 104(16):1887-93.","DOI":"10.1161\/hc4101.097518"},{"issue":"5","key":"10.1016\/j.autrev.2026.104073_bb0525","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s00296-013-2875-0","article-title":"Higher circulating levels of OxLDL % of LDL are associated with subclinical atherosclerosis in female patients with systemic lupus erythematosus","volume":"34","author":"Ahmad","year":"2014","journal-title":"Rheumatol Int"},{"issue":"2","key":"10.1016\/j.autrev.2026.104073_bb0530","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1046\/j.1365-2249.1997.d01-1019.x","article-title":"Oxidized low-density lipoprotein (Ox-LDL) but not LDL aggravates the manifestations of experimental antiphospholipid syndrome (APS)","volume":"108","author":"George","year":"1997","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104073_bb0535","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.bbrc.2005.12.211","article-title":"Expression of lectin-like oxidized LDL receptor-1 in smooth muscle cells after vascular injury","volume":"341","author":"Eto","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"10.1016\/j.autrev.2026.104073_bb0540","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1161\/01.RES.0000124920.09738.26","article-title":"Glucose enhances human macrophage LOX-1 expression: role for LOX-1 in glucose-induced macrophage foam cell formation","volume":"94","author":"Li","year":"2004","journal-title":"Circ Res"},{"issue":"5","key":"10.1016\/j.autrev.2026.104073_bb0545","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1161\/CIRCRESAHA.108.190116","article-title":"Mediation of electronegative low-density lipoprotein signaling by LOX-1: a possible mechanism of endothelial apoptosis","volume":"104","author":"Lu","year":"2009","journal-title":"Circ Res"},{"issue":"40","key":"10.1016\/j.autrev.2026.104073_bb0550","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1093\/eurheartj\/eht532","article-title":"Endothelial overexpression of LOX-1 increases plaque formation and promotes atherosclerosis in vivo","volume":"35","author":"Akhmedov","year":"2014","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.autrev.2026.104073_bb0555","doi-asserted-by":"crossref","first-page":"e009874","DOI":"10.1161\/JAHA.118.009874","article-title":"High levels of soluble lectinlike oxidized low-density lipoprotein receptor-1 are associated with carotid plaque inflammation and increased risk of ischemic stroke","volume":"8","author":"Markstad","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"10.1016\/j.autrev.2026.104073_bb0560","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229184","article-title":"LOX-1: A potential driver of cardiovascular risk in SLE patients","volume":"15","author":"Sagar","year":"2020","journal-title":"PloS One"},{"issue":"8","key":"10.1016\/j.autrev.2026.104073_bb0565","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1161\/01.ATV.0000229218.97976.43","article-title":"Scavenger receptors in atherosclerosis: beyond lipid uptake","volume":"26","author":"Moore","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"22","key":"10.1016\/j.autrev.2026.104073_bb0570","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1161\/01.CIR.0000103624.14436.4B","article-title":"Inflammatory\/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment","volume":"108","author":"Ansell","year":"2003","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.autrev.2026.104073_bb0575","article-title":"How does HDL participate in atherogenesis? Antioxidant activity versus role in reverse cholesterol transport","volume":"14","author":"Durrington","year":"2025","journal-title":"Antioxidants (Basel)"},{"issue":"6","key":"10.1016\/j.autrev.2026.104073_bb0580","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1172\/JCI118345","article-title":"Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures","volume":"96","author":"Van Lenten","year":"1995","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.autrev.2026.104073_bb0585","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.pharmthera.2005.06.023","article-title":"Myeloperoxidase and its contributory role in inflammatory vascular disease","volume":"111","author":"Lau","year":"2006","journal-title":"Pharmacol Ther"},{"issue":"45","key":"10.1016\/j.autrev.2026.104073_bb0590","doi-asserted-by":"crossref","first-page":"30825","DOI":"10.1074\/jbc.M109.047605","article-title":"Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle","volume":"284","author":"Undurti","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.autrev.2026.104073_bb0595","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3389\/fphys.2020.00433","article-title":"Targeting myeloperoxidase (MPO) mediated oxidative stress and inflammation for reducing brain ischemia injury: potential application of natural compounds","volume":"11","author":"Chen","year":"2020","journal-title":"Front Physiol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104073_bb0600","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1161\/01.ATV.0000163262.83456.6d","article-title":"Myeloperoxidase and cardiovascular disease","volume":"25","author":"Nicholls","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104073_bb0605","article-title":"Understanding myeloperoxidase-induced damage to HDL Structure and function in the vessel wall: implications for HDL-based therapies","volume":"11","author":"Marsche","year":"2022","journal-title":"Antioxidants (Basel)"},{"issue":"7","key":"10.1016\/j.autrev.2026.104073_bb0610","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1080\/14728222.2020.1762177","article-title":"Myeloperoxidase: a potential therapeutic target for coronary artery disease","volume":"24","author":"Chaikijurajai","year":"2020","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.autrev.2026.104073_bb0615","first-page":"11(5)","article-title":"Unexpected role of MPO-oxidized LDLs in atherosclerosis: in between inflammation and its resolution","volume":"28","author":"Tangeten","year":"2022","journal-title":"Antioxidants (Basel)"},{"issue":"2","key":"10.1016\/j.autrev.2026.104073_bb0620","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2174\/1568026611313020004","article-title":"Myeloperoxidase: expressing inflammation and oxidative stress in cardiovascular disease","volume":"13","author":"Anatoliotakis","year":"2013","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.autrev.2026.104073_bb0625","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1196\/annals.1422.025","article-title":"Autoantibodies against protective molecules--C1q, C-reactive protein, serum amyloid P, mannose-binding lectin, and apolipoprotein A1: prevalence in systemic lupus erythematosus","volume":"1108","author":"Shoenfeld","year":"2007","journal-title":"Ann N Y Acad Sci"},{"issue":"9","key":"10.1016\/j.autrev.2026.104073_bb0630","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1002\/art.27546","article-title":"Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis","volume":"62","author":"Vuilleumier","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2026.104073_bb0635","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/art.27286","article-title":"Antibodies to apolipoprotein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus","volume":"62","author":"O\u2019Neill","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2026.104073_bb0640","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10067-013-2399-8","article-title":"Anti-apolipoprotein A-1 antibodies and carotid intima-media thickness in Egyptian women with systemic lupus erythematosus","volume":"33","author":"Radwan","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104073_bb0645","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13075-015-0539-z","article-title":"IgG anti-apolipoprotein A-1 antibodies in patients with systemic lupus erythematosus are associated with disease activity and corticosteroid therapy: an observational study","volume":"17","author":"Croca","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.autrev.2026.104073_bb0650","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3109\/03009741003742755","article-title":"Anti-apoA-1 IgG and oxidized LDL are raised in rheumatoid arthritis (RA): potential associations with cardiovascular disease and RA disease activity","volume":"39","author":"Vuilleumier","year":"2010","journal-title":"Scand J Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104073_bb0655","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2796.2012.02530.x","article-title":"Anti-apolipoprotein A-1 IgG in patients with myocardial infarction promotes inflammation through TLR2\/CD14 complex","volume":"272","author":"Pagano","year":"2012","journal-title":"J Intern Med"},{"key":"10.1016\/j.autrev.2026.104073_bb0660","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13075-015-0539-z","article-title":"IgG anti-apolipoprotein A-1 antibodies in patients with systemic lupus erythematosus are associated with disease activity and corticosteroid therapy: an observational study","volume":"17","author":"Croca","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1016\/j.autrev.2026.104073_bb0665","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1160\/TH17-03-0221","article-title":"Serum levels of anti-PON1 and anti-HDL antibodies as potential biomarkers of premature atherosclerosis in systemic lupus erythematosus","volume":"117","author":"Lopez","year":"2017","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.autrev.2026.104073_bb0670","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/eurheartj\/ehq521","article-title":"Anti-Apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability","volume":"32","author":"Montecucco","year":"2011","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.autrev.2026.104073_bb0675","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1194\/jlr.M20063-JLR200","article-title":"Omega-carboxyl variants of 7-ketocholesteryl esters are ligands for beta(2)-glycoprotein I and mediate antibody-dependent uptake of oxidized LDL by macrophages","volume":"43","author":"Liu","year":"2002","journal-title":"J Lipid Res"},{"issue":"4","key":"10.1016\/j.autrev.2026.104073_bb0680","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1194\/jlr.M200329-JLR200","article-title":"Circulating oxidized LDL forms complexes with beta2-glycoprotein I: implication as an atherogenic autoantigen","volume":"44","author":"Kobayashi","year":"2003","journal-title":"J Lipid Res"},{"issue":"3","key":"10.1016\/j.autrev.2026.104073_bb0685","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1309\/2AUE6HD4W6TLEUU5","article-title":"Oxidized low-density lipoprotein\/beta2-glycoprotein I complexes and autoantibodies to oxLig-1\/beta2-glycoprotein I in patients with systemic lupus erythematosus and antiphospholipid syndrome","volume":"121","author":"Lopez","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.autrev.2026.104073_bb0690","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1196\/annals.1361.073","article-title":"OxLDL\/beta2GPI complexes and autoantibodies in patients with systemic lupus erythematosus, systemic sclerosis, and antiphospholipid syndrome: pathogenic implications for vascular involvement","volume":"1051","author":"Lopez","year":"2005","journal-title":"Ann N Y Acad Sci"},{"issue":"7","key":"10.1016\/j.autrev.2026.104073_bb0695","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1191\/0961203306lu2337oa","article-title":"Atherogenic oxidized low-density lipoprotein\/beta2-glycoprotein I (oxLDL\/beta2GPI) complexes in patients with systemic lupus erythematosus and antiphospholipid syndrome","volume":"15","author":"Matsuura","year":"2006","journal-title":"Lupus"},{"issue":"4","key":"10.1016\/j.autrev.2026.104073_bb0700","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/08916930902828247","article-title":"oxLDL\/beta2GPI complex and anti-oxLDL\/beta2GPI in SLE: prevalence and correlates","volume":"42","author":"Bassi","year":"2009","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2026.104073_bb0705","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/621270","article-title":"Cardiovascular risk factors in the antiphospholipid syndrome","volume":"2014","author":"da Silva","year":"2014","journal-title":"J Immunol Res"},{"key":"10.1016\/j.autrev.2026.104073_bb0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102813","article-title":"Cardiovascular disease risk in antiphospholipid syndrome: Thrombo-inflammation and atherothrombosis","volume":"128","author":"Tektonidou","year":"2022","journal-title":"J Autoimmun"},{"issue":"12","key":"10.1016\/j.autrev.2026.104073_bb0715","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1177\/0961203307084170","article-title":"Distinguished effects of antiphospholipid antibodies and anti-oxidized LDL antibodies on oxidized LDL uptake by macrophages","volume":"16","author":"Kobayashi","year":"2007","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.autrev.2026.104073_bb0720","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/ard.2004.023952","article-title":"Premature atherosclerosis in primary antiphospholipid syndrome: preliminary data","volume":"64","author":"Ames","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2026.104073_bb0725","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1177\/0961203309357765","article-title":"High-density lipoprotein inversely relates to its specific autoantibody favoring oxidation in thrombotic primary antiphospholipid syndrome","volume":"19","author":"Ames","year":"2010","journal-title":"Lupus"},{"issue":"4","key":"10.1016\/j.autrev.2026.104073_bb0730","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/intimm\/dxh229","article-title":"Role of reactive oxygen species and p38 MAPK in the induction of the pro-adhesive endothelial state mediated by IgG from patients with anti-phospholipid syndrome","volume":"17","author":"Simoncini","year":"2005","journal-title":"Int Immunol"},{"issue":"8","key":"10.1016\/j.autrev.2026.104073_bb0735","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1096\/fj.201701536R","article-title":"Endothelial microRNAs regulating the NF-\u00ce\u00b0B pathway and cell adhesion molecules during inflammation","volume":"32","author":"Zhong","year":"2018","journal-title":"FASEB J"},{"issue":"4","key":"10.1016\/j.autrev.2026.104073_bb0740","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1161\/CIRCRESAHA.115.306301","article-title":"Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis","volume":"118","author":"Gimbrone","year":"2016","journal-title":"Circ Res"},{"issue":"3","key":"10.1016\/j.autrev.2026.104073_bb0745","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2249.1994.tb06107.x","article-title":"Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long term prospective study","volume":"97","author":"Spronk","year":"1994","journal-title":"Clin Exp Immunol"},{"issue":"8","key":"10.1016\/j.autrev.2026.104073_bb0750","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1177\/0961203314528061","article-title":"Cell adhesion molecules as potential biomarkers of nephritis, damage and accelerated atherosclerosis in patients with SLE","volume":"23","author":"Skeoch","year":"2014","journal-title":"Lupus"},{"issue":"12","key":"10.1016\/j.autrev.2026.104073_bb0755","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1177\/0961203318796285","article-title":"Relationship between serum vascular cell adhesion molecule-1 and endothelin-1 levels with organ involvement and disease activity in systemic lupus erythematosus patients","volume":"27","author":"Hajialilo","year":"2018","journal-title":"Lupus"},{"issue":"10","key":"10.1016\/j.autrev.2026.104073_bb0760","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/art.10542","article-title":"Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome","volume":"46","author":"Delgado","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.autrev.2026.104073_bb0765","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1001\/jama.2009.1346","article-title":"Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome","volume":"302","author":"Charakida","year":"2009","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.autrev.2026.104073_bb0770","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1161\/CIRCRESAHA.116.309692","article-title":"Neutrophil Extracellular Traps in Atherosclerosis and Atherothrombosis","volume":"120","author":"Doring","year":"2017","journal-title":"Circ Res"},{"issue":"2","key":"10.1016\/j.autrev.2026.104073_bb0775","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1083\/jcb.200606027","article-title":"Novel cell death program leads to neutrophil extracellular traps","volume":"176","author":"Fuchs","year":"2007","journal-title":"J Cell Biol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104073_bb0780","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1083\/jcb.201006052","article-title":"Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps","volume":"191","author":"Papayannopoulos","year":"2010","journal-title":"J Cell Biol"},{"issue":"14","key":"10.1016\/j.autrev.2026.104073_bb0785","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1016\/j.febslet.2010.06.006","article-title":"Activated endothelial cells induce neutrophil extracellular traps and are susceptible to NETosis-mediated cell death","volume":"584","author":"Gupta","year":"2010","journal-title":"FEBS Lett"},{"issue":"73","key":"10.1016\/j.autrev.2026.104073_bb0790","doi-asserted-by":"crossref","first-page":"73ra20","DOI":"10.1126\/scitranslmed.3001201","article-title":"Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus","volume":"3","author":"Garcia-Romo","year":"2011","journal-title":"Sci Transl Med"},{"issue":"42","key":"10.1016\/j.autrev.2026.104073_bb0795","doi-asserted-by":"crossref","first-page":"44123","DOI":"10.1074\/jbc.M405883200","article-title":"Induction of genes mediating interferon-dependent extracellular trap formation during neutrophil differentiation","volume":"279","author":"Martinelli","year":"2004","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.autrev.2026.104073_bb0800","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1160\/TH11-09-0650","article-title":"Presence of luminal neutrophil extracellular traps in atherosclerosis","volume":"107","author":"Megens","year":"2012","journal-title":"Thromb Haemost"},{"issue":"8029","key":"10.1016\/j.autrev.2026.104073_bb0805","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41586-024-07803-4","article-title":"DNA-sensing inflammasomes cause recurrent atherosclerotic stroke","volume":"633","author":"Cao","year":"2024","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.autrev.2026.104073_bb0810","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.4049\/jimmunol.0902199","article-title":"A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs","volume":"184","author":"Denny","year":"2010","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104073_bb0815","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/91070","article-title":"Mutation of DNASE1 in people with systemic lupus erythematosus","volume":"28","author":"Yasutomo","year":"2001","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.autrev.2026.104073_bb0820","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10067-015-3111-y","article-title":"Deoxyribonuclease I gene polymorphism and susceptibility to systemic lupus erythematosus","volume":"35","author":"Mohammadoo-Khorasani","year":"2016","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104073_bb0825","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ydbio.2017.06.028","article-title":"Dnases in health and disease","volume":"429","author":"Keyel","year":"2017","journal-title":"Dev Biol"},{"issue":"21","key":"10.1016\/j.autrev.2026.104073_bb0830","doi-asserted-by":"crossref","first-page":"9813","DOI":"10.1073\/pnas.0909927107","article-title":"Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis","volume":"107","author":"Hakkim","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.autrev.2026.104073_bb0835","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4049\/jimmunol.1100450","article-title":"Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus","volume":"187","author":"Villanueva","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2026.104073_bb0840","doi-asserted-by":"crossref","first-page":"3872367","DOI":"10.1155\/2020\/3872367","article-title":"The role of matrix metalloproteinase-9 in atherosclerotic plaque instability","volume":"2020","author":"Li","year":"2020","journal-title":"Mediators Inflamm"},{"issue":"2","key":"10.1016\/j.autrev.2026.104073_bb0845","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1046\/j.1365-2249.2002.01758.x","article-title":"Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus","volume":"127","author":"Faber-Elmann","year":"2002","journal-title":"Clin Exp Immunol"},{"issue":"7","key":"10.1016\/j.autrev.2026.104073_bb0850","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1136\/annrheumdis-2013-204837","article-title":"Neutrophil extracellular traps induce endothelial dysfunction in systemic lupus erythematosus through the activation of matrix metalloproteinase-2","volume":"74","author":"Carmona-Rivera","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2026.104073_bb0855","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.atherosclerosis.2005.05.039","article-title":"Altered expression balance of matrix metalloproteinases and their inhibitors in human carotid plaque disruption: results of quantitative tissue analysis using real-time RT-PCR method","volume":"185","author":"Higashikata","year":"2006","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.autrev.2026.104073_bb0860","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2741\/4378","article-title":"Regulation and involvement of matrix metalloproteinases in vascular diseases","volume":"21","author":"Amin","year":"2016","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"12","key":"10.1016\/j.autrev.2026.104073_bb0870","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2025.103920","article-title":"The roles of S100A8\/A9 and S100A12 in autoimmune diseases: mechanisms, biomarkers, and therapeutic potential","volume":"24","author":"Wang","year":"2025","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.autrev.2026.104073_bb0875","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/0961203316655208","article-title":"Pro-inflammatory S100 proteins are associated with glomerulonephritis and anti-dsDNA antibodies in systemic lupus erythematosus","volume":"26","author":"Tyd\u00e9n","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2026.104073_bb0880","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.936534","article-title":"Serum calprotectin - a NET product - as a biomarker of disease activity in patients with systemic lupus erythematosus: a single-center case-control study from Poland","volume":"28","author":"Homa-Mlak","year":"2022","journal-title":"Med Sci Monit"},{"issue":"1","key":"10.1016\/j.autrev.2026.104073_bb0885","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s41927-022-00268-w","article-title":"Serum S100A8\/A9 concentrations are associated with neuropsychiatric involvement in systemic lupus erythematosus: a cross-sectional study","volume":"6","author":"Zervides","year":"2022","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.autrev.2026.104073_bb0890","doi-asserted-by":"crossref","first-page":"1326751","DOI":"10.3389\/fimmu.2023.1326751","article-title":"Serum S100A8\/A9 and MMP-9 levels are elevated in systemic lupus erythematosus patients with cognitive impairment","volume":"14","author":"Munoz-Grajales","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104073_bb0895","doi-asserted-by":"crossref","unstructured":"Turnier JL, Fall N, Thornton S, Witte D, Bennett MR, Appenzeller S et al. Urine S100 proteins as potential biomarkers of lupus nephritis activity. Arthritis Res Ther 2017 Octo19(1):242.","DOI":"10.1186\/s13075-017-1444-4"},{"key":"10.1016\/j.autrev.2026.104073_bb0900","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108375","article-title":"Differential analysis of serum and urine S100 proteins in juvenile-onset systemic lupus erythematosus (jSLE)","volume":"214","author":"Donohue","year":"2020","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2026.104073_bb0905","article-title":"S100A8 in Serum, Urine, and Saliva as a Potential Biomarker for Systemic Lupus Erythematosus","volume":"13","author":"Kim","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104073_bb0910","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/0961203315598015","article-title":"Elevated expressions of myeloid-related proteins-8 and -14 are danger biomarkers for lupus nephritis","volume":"25","author":"Tantivitayakul","year":"2016","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.autrev.2026.104073_bb0915","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13075-023-03057-z","article-title":"Expression of S100A8 protein on B cells is associated with disease activity in patients with systemic lupus erythematosus","volume":"25","author":"Kitagori","year":"2023","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2026.104073_bb0920","first-page":"92","article-title":"S100\/calgranulins EN-RAGEing the blood vessels: implications for inflammatory responses and atherosclerosis","volume":"1","author":"Hofmann Bowman","year":"2011","journal-title":"Am J Cardiovasc Dis"},{"issue":"12","key":"10.1016\/j.autrev.2026.104073_bb0925","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1161\/ATVBAHA.115.302072","article-title":"S100A12 and the S100\/Calgranulins: emerging biomarkers for atherosclerosis and possibly therapeutic targets","volume":"35","author":"Oesterle","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.autrev.2026.104073_bb0930","doi-asserted-by":"crossref","first-page":"1394137","DOI":"10.3389\/fcvm.2024.1394137","article-title":"S100a8\/A9 proteins: critical regulators of inflammation in cardiovascular diseases","volume":"11","author":"Sun","year":"2024","journal-title":"Front Cardiovasc Med"},{"issue":"11","key":"10.1016\/j.autrev.2026.104073_bb0935","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1093\/rheumatology\/ket263","article-title":"Increased serum levels of S100A8\/A9 and S100A12 are associated with cardiovascular disease in patients with inactive systemic lupus erythematosus","volume":"52","author":"Tyd\u00e9n","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2026.104073_bb0940","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cyto.2007.09.007","article-title":"TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK\/Fn14 pathway in health and disease","volume":"40","author":"Burkly","year":"2007","journal-title":"Cytokine"},{"key":"10.1016\/j.autrev.2026.104073_bb0945","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3389\/fimmu.2014.00003","article-title":"TWEAK\/Fn14 axis: a promising target for the treatment of cardiovascular diseases","volume":"5","author":"Blanco-Colio","year":"2014","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104073_bb0950","doi-asserted-by":"crossref","first-page":"R143","DOI":"10.1186\/ar2816","article-title":"Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study","volume":"11","author":"Schwartz","year":"2009","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2026.104073_bb0955","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/0886022X.2020.1853568","article-title":"Diagnostic value of TWEAK for predicting active lupus nephritis in patients with systemic lupus erythematosus: a systematic review and meta-analysis","volume":"43","author":"Ma","year":"2021","journal-title":"Ren Fail"},{"issue":"1","key":"10.1016\/j.autrev.2026.104073_bb0960","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2018-000298","article-title":"Urine TWEAK level as a biomarker for early response to treatment in active lupus nephritis: a prospective multicentre study","volume":"6","author":"Suttichet","year":"2019","journal-title":"Lupus Sci Med"},{"issue":"6","key":"10.1016\/j.autrev.2026.104073_bb0965","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00011-016-0930-5","article-title":"Serum TWEAK as a biomarker for disease activity of systemic lupus erythematosus","volume":"65","author":"Choe","year":"2016","journal-title":"Inflamm Res"},{"issue":"4","key":"10.1016\/j.autrev.2026.104073_bb0970","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1177\/0961203320904997","article-title":"Serum and urine TNF-like weak inducer of apoptosis, monocyte chemoattractant protein-1 and neutrophil gelatinase-associated lipocalin as biomarkers of disease activity in patients with systemic lupus erythematosus","volume":"29","author":"Mirioglu","year":"2020","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.autrev.2026.104073_bb0980","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/cmi.2010.84","article-title":"IFN-\u03b1 production by human mononuclear cells infected with varicella-zoster virus through TLR9-dependent and -independent pathways","volume":"8","author":"Yu","year":"2011","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.autrev.2026.104073_bb0985","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.3389\/fimmu.2018.01957","article-title":"Up-regulation of TLR7-mediated IFN-\u00ce\u00b1 production by plasmacytoid dendritic cells in patients with systemic lupus erythematosus","volume":"9","author":"Sakata","year":"2018","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.autrev.2026.104073_bb0990","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2021109622","article-title":"TLR2 and TLR7 mediate distinct immunopathological and antiviral plasmacytoid dendritic cell responses to SARS-CoV-2 infection","volume":"41","author":"van der Sluis","year":"2022","journal-title":"EMBO J"},{"issue":"5","key":"10.1016\/j.autrev.2026.104073_bb0995","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s12026-023-09380-6","article-title":"Potential role of EBV and Toll-like receptor 9 ligand in patients with systemic lupus erythematosus","volume":"71","author":"Izadi","year":"2023","journal-title":"Immunol Res"},{"key":"10.1016\/j.autrev.2026.104073_bb1000","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/370516","article-title":"Epstein-Barr virus and systemic lupus erythematosus","volume":"2012","author":"Draborg","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.autrev.2026.104073_bb1005","doi-asserted-by":"crossref","first-page":"1188330","DOI":"10.3389\/fimmu.2023.1188330","article-title":"Cardiovascular involvement in Epstein-Barr virus infection","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104073_bb1010","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12985-018-0937-3","article-title":"Human cytomegalovirus infection and coronary heart disease: a systematic review","volume":"15","author":"Du","year":"2018","journal-title":"Virol J"},{"issue":"4","key":"10.1016\/j.autrev.2026.104073_bb1015","doi-asserted-by":"crossref","DOI":"10.1016\/j.trre.2024.100860","article-title":"Cytomegalovirus infection and cardiovascular outcomes in abdominal organ transplant recipients: a systematic review and meta-analysis","volume":"38","author":"Arvanitis","year":"2024","journal-title":"Transplant Rev (Orlando)"},{"issue":"4","key":"10.1016\/j.autrev.2026.104073_bb1020","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/s41401-022-00998-0","article-title":"Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies","volume":"44","author":"Xu","year":"2023","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"10.1016\/j.autrev.2026.104073_bb1025","first-page":"1","article-title":"Coronary implications of COVID-19","volume":"34","author":"Triantafyllis","year":"2025","journal-title":"Med Princ Pract"},{"issue":"2","key":"10.1016\/j.autrev.2026.104073_bb1030","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001580","article-title":"Antiphospholipid antibodies in COVID-19: a meta-analysis and systematic review","volume":"7","author":"Taha","year":"2021","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2026.104073_bb1035","doi-asserted-by":"crossref","first-page":"1544218","DOI":"10.3389\/fimmu.2025.1544218","article-title":"Prevalence, incidence, and risk factors for herpes zoster in systemic lupus erythematosus: a systematic review and meta-analysis","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104073_bb1040","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/art.39855","article-title":"Herpes Zoster and the risk of stroke in patients with autoimmune diseases","volume":"69","author":"Calabrese","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"23","key":"10.1016\/j.autrev.2026.104073_bb1045","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.027451","article-title":"Herpes Zoster and Long-Term Risk of Cardiovascular Disease","volume":"11","author":"Curhan","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"30","key":"10.1016\/j.autrev.2026.104073_bb1050","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1093\/eurheartj\/ehaf230","article-title":"Live zoster vaccination and cardiovascular outcomes: a nationwide, South Korean study","volume":"46","author":"Lee","year":"2025","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.autrev.2026.104073_bb1055","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.36849\/JDD.7415","article-title":"Recombinant Zoster vaccine reduces 3-year cardiovascular risk: insights from a multi-centered database","volume":"22","author":"Helm","year":"2023","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104073_bb1060","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.ard.2025.01.045","article-title":"Effectiveness and safety of the recombinant zoster vaccine in individuals \u226550 years of age with rheumatoid arthritis: a matched cohort and self-controlled case series study","volume":"84","author":"Rayens","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2026.104073_bb1065","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"36","key":"10.1016\/j.autrev.2026.104073_bb1070","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1093\/eurheartj\/ehaf384","article-title":"Vaccination as a new form of cardiovascular prevention: a European Society of Cardiology clinical consensus statement","volume":"46","author":"Heidecker","year":"2025","journal-title":"Eur Heart J"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899722600087X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899722600087X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T02:01:50Z","timestamp":1783130510000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156899722600087X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":214,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S156899722600087X"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104073","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inflammatory biomarkers of atherosclerosis in SLE that may improve SLE-specific cardiovascular risk assessment tools","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104073"}}